Small-incision lenticule extraction for moderate to high myopia provides high rates of patient satisfaction, refractive predictability and is a safe procedure.
Small-incision lenticule extraction for moderate to high myopia provides high rates of patient satisfaction, refractive predictability and is a safe procedure.
Dr Anders Vestergaard et al., Department of Ophthalmology, Aarhus University Hospital, Aarhus, Denmark, conducted a prospective clinical study on 144 patients with moderate to high myopia.
Small-incision lenticule extraction was performed with a femtosecond laser and manually extracted without flap creation. Each patient was treated and assessed for three months. One randomly selected eye of each patient was used for the statistical analyses.
Mean preoperative spherical equivalent was −7.18 D ± 1.57. In 40% of eyes with emmetropia as target refraction the uncorrected distance visual acuity was 0.1 logMAR or less one day postoperatively. This increased to 73% at three months postoperatively.
Mean corrected distance visual acuity (CDVA) significantly improved from -0.01 preoperatively to -0.03 three months postoperatively. Of the eyes studied, six lost one line of CDVA after three months and none of the eyes lost two lines or more of CDVA.
Achieved mean refraction was −0.09 ± 0.45 D from the attempted refraction. Out of the eyes included, 77% were within ±0.50 D and 95% were within ±1.00 D. As for patient satisfaction, 95% of the patients recommended the procedure to others.
To view the abstract visit the
Journal of Cataract and Refractive Surgery.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.